Tuesday broker round-up
18th May 2021 14:00
(Sharecast News) - BP: Barclays upgrades to top pick with a target price of 475p.
Read moreOxford Biomedica ups revenue forecast as AstraZeneca lifts vaccine output
18th May 2021 08:13
(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
Read moreMonday broker round-up
17th May 2021 14:38
(Sharecast News) - Diploma: Numis upgrades to add with a target price of 3,250p.
Read moreUK eases lockdown restrictions despite Indian variant threat
17th May 2021 10:16
(Sharecast News) - The UK relaxed social and economic restrictions on Monday despite the looming threat of the Indian Covid-19 variant.
Read moreFriday broker round-up
14th May 2021 12:57
(Sharecast News) - NCC Group: Canaccord upgrades to buy with a target price of 318p.
Read moreUK prepares to 'flex' vaccination program to tackle Indian Covid-19 variant
14th May 2021 11:16
(Sharecast News) - UK vaccines minister Nadhim Zahawi said on Friday that the government was gearing up to "flex" its inoculation program in order to tackle the new coronavirus variant first detected in India.
Read moreWednesday broker round-up
12th May 2021 13:55
(Sharecast News) - Air Partner: Canaccord reiterates buy with a target price of 100p.
Read moreAstraZeneca shareholders approve Alexion acquisition
11th May 2021 13:59
(Sharecast News) - AstraZeneca's acquisition of Alexion Pharmaceuticals is set to close in the third quarter after shareholders voted in favour of the deal.
Read moreMonday broker round-up
10th May 2021 13:05
(Sharecast News) - St Modwen: Liberum downgrades to hold with a target price of 542p.
Read moreSunday newspaper round-up: AstraZeneca, Virgin Atlantic, Boohoo
9th May 2021 20:21
(Sharecast News) - AstraZeneca boss Pascal Soriot was last night at the centre of an extraordinary row among City investors over his multi-million-pound bonus. The French chief executive has been lauded for rolling out Astra's life-saving Covid vaccine at no profit, as well as fighting off predatory buyers and boosting the company's share price since he took charge in 2012. But Astra's major shareholders are understood to have been locked in heated talks for days after the drugs giant proposed to boost his bonus and performance-related share award by £2.3million to £12million. - Financial Mail on Sunday
Read moreUK to give under 40s alternative to AstraZeneca vaccine
7th May 2021 09:49
(Sharecast News) - The UK government decided on Friday to offer people under 40 an alternative to the AstraZeneca Covid-19 vaccine, reported Bloomberg.
Read moreAstraZeneca's Imfinzi demonstrates benefit in combination with antibody
7th May 2021 07:42
(Sharecast News) - AstraZeneca reported on Friday that 'Imfinzi' and tremelimumab with chemotherapy demonstrated an overall survival benefit in the 'POSEIDON' trial for first-line stage four non-small cell lung cancer, making it the first phase 3 trial to demonstrate an overall survival benefit with tremelimumab.
Read moreThursday broker round-up
6th May 2021 13:43
(Sharecast News) - National Grid: Berenberg upgrades to buy with a target price of 1,100p.
Read moreAstraZeneca's Forxiga gets US approval for chronic kidney disease
4th May 2021 07:23
(Sharecast News) - AstraZeneca said on Tuesday that Farxiga has been approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes.
Read moreEU nations push for Valneva Covid-19 vaccine approval
30th Apr 2021 15:35
(Sharecast News) - Some countries from the European Union, including France and Germany, are pushing Brussels to strike a deal to buy Valneva's Covid-19 vaccine candidate despite a recent setback in talks.
Read more